In a study using an ICAM1-binding DBLβ3 domain from a Group A PfEMP1 variant with an EPCR-binding CIDRα1 domain, higher IgG levels against the DBLβ3 at enrolment were significantly associated with a reduced risk of high‐density clinical malaria (fever + ≥10,000 parasites/μL) and of progression to SM during follow-up (69 weeks) (84). This evidence concerns the gene ICAM1 and systemic mastocytosis.